institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

Published loading...Updated

Former X CEO Linda Yaccarino Has a New Job

MIAMI, UNITED STATES, AUG 5 – Linda Yaccarino joins eMed to lead strategic partnerships in digital health focused on GLP-1 drugs, an industry expected to reach $100 billion annually by 2030, analysts say.

  • Amid her recent exit from X, eMed Population Health on Tuesday announced Linda Yaccarino as its new CEO, pivoting into health care.
  • Following Musk’s platform overhaul, Yaccarino faced repeated PR crises over antisemitic content and advertiser backlash, despite being hired in 2023 to repair relations at X.
  • Focused on GLP-1/GIP population health management, eMed claims to develop a platform supporting weight loss and diabetes drugs, having raised $22 million by 2022.
  • The board of directors called Yaccarino's arrival a rare opportunity to accelerate digital-first health programs, citing her ability to negotiate new partnerships for expanding employer and government deals.
  • Goldman Sachs analysts expect 15 million U.S. adults to be on anti-obesity drugs by 2030, forecasting a $100 billion market, and EMed claims it can reduce program costs by up to 50%.
Insights by Ground AI
Does this summary seem wrong?

31 Articles

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 61% of the sources are Center
61% Center

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

UPI broke the news in Washington, United States on Tuesday, August 5, 2025.
Sources are mostly out of (0)